Impaired cardiac function including any of the following:\r\n* Myocardial infarction within 6 months of starting study drug\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an anti-hypertensive regimen)
A past medical history of other clinically significant cardiovascular disease (eg, uncontrolled hypertension, history of labile hypertension, history of poor compliance with an antihypertensive regimen).
Impaired cardiac function including any of the following:\r\n* Myocardial infarction within 6 months of starting study drug\r\n* A past medical history of clinically significant electrocardiography (ECG) abnormalities, including corrected QT (QTc) 481 ms or greater\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
EXCLUSION - PARTICIPANT: Clinically significant cardiac disease or impaired cardiac function, including any of the following: \r\n* Clinically significant and/or uncontrolled heart disease such as congestive heart failure (New York Heart Association grade >= 2) uncontrolled hypertension, or clinically significant arrhythmia currently requiring medical treatment\r\n* Fridericia's correction formula (QTcF) > 470 msec for females, or > 450 msec for males, on screening electrocardiography (ECG) or congenital long QT syndrome\r\n* Acute myocardial infarction or unstable angina pectoris < 6 months prior to screening
Known impaired cardiac function including any of the following:\r\n* History or presence of clinically significant ventricular or atrial tachyarrhythmias;\r\n* Clinically significant resting bradycardia (< 50 beats per minute);\r\n* Myocardial infarction within 1 year of starting study drug;\r\n* Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
Cardiovascular disorders such as:\r\n* Inability to monitor the QT interval on electrocardiogram (ECG)\r\n* Complete left bundle branch block\r\n* Right bundle branch block plus left anterior or posterior hemiblock\r\n* Use of a ventricular-paced pacemaker\r\n* Congenital long QT syndrome or a known family history of long QT syndrome\r\n* Clinically significant resting bradycardia (< 50 beats per minute)\r\n* Corrected QT interval (QTc) > 450 msec on baseline ECG; if QTc > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction within 6 months prior to starting study\r\n* History of unstable angina within 6 months prior to study entry\r\n* Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension)\r\n* History of or presence of clinically significant ventricular or atrial tachyarrhythmias
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment)\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm); patients with pacemakers are eligible if HR >= 50 bpm\r\n* Screening electrocardiogram (ECG) with a corrected QT (QTc) > 470 msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina =< 12 months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: \r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment)\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm); patients with pacemakers are eligible if HR >= 50 bpm\r\n* Screening electrocardiogram (ECG) with a corrected QT (QTc) > 470 msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Myocardial infarction or unstable angina =< 12 months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within 3 months\r\n* Acute myocardial infarction within 3 months\r\n* Corrected QT interval (QTc) > 480 msec on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any of the following: history or presence of ventricular tachyarrhythmia; presence of unstable atrial fibrillation (ventricular response > 100 beats per minute [bpm]); patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria; clinically significant resting bradycardia (< 50 bpm); angina pectoris or acute myocardial infarction =< 3 months prior to starting study drug; other clinically significant heart disease (e.g., symptomatic congestive heart failure; uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within 3 months\r\n* Acute myocardial infarction within 3 months\r\n* Fridericia QT (QTcF) > 450 msec for males and > 470 msec for females on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function including any of the following: Screening ECG with a QTc >450 msec. The QTc interval will be calculated by Fridericia's correction factor (QTcF) at Screening and on Day 5 prior to the first dose of AC220. The QTcF will be derived from the average QTcF in triplicate.; If QTcF>450 msec on Day 5, AC220 will not be given; Patients with congenital long QT syndrome; History or presence of sustained ventricular tachycardia requiring medical intervention; Any history of clinically significant ventricular fibrillation or torsades de pointes; Known history of second or third degree heart block (may be eligible if the patient currently has a pacemaker); Sustained heart rate of <50/minute on pre-entry ECG; Right bundle branch block + left anterior hemiblock (bifascicular block); Patients with myocardial infarction or unstable angina within 6 months prior to starting study drug; CHF NY Heart Association class III or IV.
Patient has a history or current evidence of clinically significant heart disease including:\r\n* Clinically significant congestive heart failure, unstable angina pectoris\r\n* Clinically significant cardiac arrhythmia\r\n* Myocardial infarction during the last 6 months, and/or a current electrocardiogram (ECG) tracing that is abnormal in the opinion of the treating Investigator\r\n* Corrected QT interval (QTc) prolongation > 480 msec (Bazett's formula)\r\n* Congenitally long QT syndrome, and/or current anti-arrhythmic therapy, and / or has received any marketed or experimental compound in the last 1 week prior to entering the study with known effects of QT prolongation
Uncontrolled intercurrent illnesses including, but not limited to unstable angina or uncontrolled cardiac arrhythmia, chronic liver disease, complete left bundle branch block, obligate use of a cardiac pacemaker, ST depression of > 1 mm in two or more leads and/or T wave inversions in two or more contiguous leads, congenital long QT syndrome, history of or presence of significant ventricular or atrial tachyarrhythmias, clinically significant resting bradycardia (< 50 beats per minute), corrected QT (QTc) > 480 ms on screening electrocardiogram that could jeopardize the patient’s ability to receive the chemotherapy described in the protocol safely
Impaired cardiac function including any one of the following:\r\n* Inability to monitor the QT interval on electrocardiogram (ECG)\r\n* Congenital long QT syndrome or a known family history of long QT syndrome\r\n* Clinically significant resting brachycardia (< 50 beats per minute)\r\n* QTc > 450 msec on baseline ECG; if QTc > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction within 12 months prior to starting study\r\n* Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension)\r\n* History of or presence of clinically significant ventricular or atrial tachyarrhythmias
A past medical history of other clinically significant cardiovascular disease - e.g., uncontrolled hypertension, history of labile hypertension or history of poor compliance with an antihypertensive regimen
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: \r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible) \r\n* Any history of ventricular fibrillation or torsade de pointes \r\n* Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm); patients with pacemakers are eligible if HR >= 50 bpm\r\n* Screening electrocardiogram (ECG) with a Fridericia's correction formula (QTcF) > 450 msec (QTcF = QT/^3 square root of RR); if potassium, magnesium, or calcium blood levels are below normal limits, consider repeating ECG after correction of these electrolytes\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block) \r\n* Patients with myocardial infarction or unstable angina =< 6 months prior to starting study drug \r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function including any of the following:\r\n* Congenital long QT syndrome or a known family history of long QT syndrome;\r\n* Corrected QT (QTc) > 450 msec;\r\n* History or presence of clinically significant ventricular or atrial tachyarrhythmias;\r\n* Clinically significant resting bradycardia (< 50 beats per minute); \r\n* Myocardial infarction within 1 year of starting study drug;\r\n* Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
Impaired cardiac function including any of the following:\r\n* Congenital long QT syndrome or a known family history of long QT syndrome\r\n* History or presence of clinically significant ventricular or atrial tachyarrhythmias\r\n* Clinically significant resting bradycardia (< 50 beats per minute)\r\n* Inability to monitor the QT interval by electrocardiogram (ECG)\r\n* Corrected QT (QTc) > 450 msec on baseline ECG; if QTc > 450 and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction within 1 year of starting study drug\r\n* Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
Impaired cardiac function or clinically significant cardiac diseases, history of arrhythmia (including ventricular fibrillation or torsade de pointes), bradycardia < 50 beats per minute (bpm), screening electrocardiogram (ECG) with prolonged corrected QT (QTc) (> 450 msec), uncontrolled hypertension or any history or presence of sustained ventricular tachyarrhythmia
Impaired cardiac function including any of the following:\r\n* Myocardial infarction within 6 months of starting study drug;\r\n* A past medical history of clinically significant ECG abnormalities\r\n* Other clinically significant heart disease (e.g. uncontrolled congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an anti-hypertensive regimen)
Impaired cardiac function including any of the following:\r\n* Inability to monitor the QT interval on electrocardiogram (ECG)\r\n* Congenital long QT syndrome or a known family history of long QT syndrome\r\n* Clinically significant resting brachycardia (< 50 beats per minute)\r\n* Corrected QT (QTc) > 450 msec on baseline ECG; NOTE: if the ECG shows a QTc interval greater than 450 msecs at screening triplicates should be performed, one minute apart to confirm the finding (after replacement of any electrolyte imbalance); if 2/3 or 3/3 of the ECGs confirm the QT prolongation (i.e. QTc interval > 450 msecs) the patient must not be included into the trial\r\n* Myocardial infarction =< 3 months prior to starting study\r\n* Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension) \r\n* History of or presence of clinically significant ventricular, atrial tachyarrhythmias or ejection fraction cutoff\r\n* Left ventricle ejection fraction < 45%\r\n* History of congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
Impaired cardiac function or clinically significant heart disease, including any one of the following: a) angina pectoris within 3 months; b) acute myocardial infarction within 3 months; c) QT interval corrected with the Fridericia formula (QTcF) greater than 450 msec for males and greater than 470 msec for females on the screening electrocardiogram (ECG); d) a past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome; e) other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within 3 months\r\n* Acute myocardial infarction within 3 months\r\n* Corrected Fridericia's QT (QTcF) > 450 msec for males and > 470 msec for females on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* New York Heart Association classification IV cardiovascular disease or symptomatic class III disease \r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Known significant cardiac abnormalities, including:\r\n* History or presence of sustained ventricular tachyarrhythmia (participants with a history of atrial arrhythmia are eligible but should be discussed with Dr. Laubach prior to enrollment)\r\n* Any history of ventricular fibrillation or torsades de pointes\r\n* Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm); participants with pacemakers are eligible if HR >= 50 bpm\r\n* QTcF interval >= 450 milliseconds on screening electrocardiogram (ECG);\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Participants with myocardial infarction or unstable angina =< 6 months prior to starting study drug\r\n* Other clinically significant heart disease (e.g. congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any of the following:\r\n* History or presence of ventricular tachyarrhythmia\r\n* Presence of unstable atrial fibrillation (ventricular response > 100 bpm) (NOTE: patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria)\r\n* Clinically significant resting bradycardia (< 50 bpm)\r\n* Angina pectoris or acute myocardial infarction =< 3 months prior to registration\r\n* Other clinically significant heart disease (e.g., symptomatic congestive heart failure; uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen)
Impaired cardiac function including any of the following:\r\n* Screening electrocardiogram (ECG) with a corrected QT interval (QTc) > 450 msec \r\n* Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm)\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina < 3 months prior to starting study drug\r\n* Congestive heart failure (CHF) New York (NY) Heart Association class III or IV
Impaired cardiac function including any one of the following:\r\n* Inability to monitor the QT interval on electrocardiogram (ECG)\r\n* Congenital long QT syndrome or a known family history of long QT syndrome\r\n* Clinically significant resting brachycardia (< 50 beats per minute)\r\n* Corrected QT (QTc) > 450 msec on baseline ECG; if QTc > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction =< 12 months prior to starting study\r\n* Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension)\r\n* History of or presence of clinically significant ventricular, atrial tachyarrhythmias or ejection fraction cutoff\r\n* Left ventricle ejection fraction < 45%\r\n* History of, congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* With permanent cardiac pacemaker\r\n* Resting bradycardia defined as < 50 beats per minute\r\n* Corrected QT using Fridericia's method (QTcF) > 480 msec on screening electrocardiogram (ECG)\r\n* Complete left bundle branch block, bifascicular block\r\n* Any clinically significant ST segment and/or T-wave abnormalities\r\n* Presence of unstable atrial fibrillation (ventricular response rate > 100 beats per minute [bpm]); patients with stable atrial fibrillation can be enrolled provided they do not meet other cardiac exclusion criteria\r\n* Symptomatic congestive heart failure (New York Heart Association [NYHA] class III-IV)
Impaired cardiac function including any of the following:\r\n* Congenital long QT syndrome or a known family history of long QT syndrome;\r\n* History or presence of clinically significant ventricular or atrial tachyarrhythmias\r\n* Clinically significant resting bradycardia (< 50 beats per minute) \r\n* Inability to monitor the QT interval by electrocardiogram (ECG)\r\n* Corrected QT interval (QTc) > 450 msec on baseline ECG; if QTc > 450 and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction within 1 year of starting study drug\r\n* Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: history or presence of sustained ventricular tachyarrhythmia; any history of ventricular fibrillation or torsade de pointes; bradycardia defined as heart rate (HR) < 50 beats per minute (bpm); patients with pacemakers are eligible if heart rate (HR) >= 50 bpm; screening ECG with a corrected QT using Fridericia's formula (QTcF) > 450 msec, right bundle branch block + left anterior hemiblock (bifascicular block), patients with myocardial infarction or unstable angina =< 6 months prior to starting study drug, other clinically significant heart disease (e.g., congestive heart failure [CHF] New York Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within 3 months\r\n* Acute myocardial infarction within 3 months\r\n* QT interval corrected using Fridericia’s formula (QTcF) > 450 msec for males and > 470 msec for females on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: * History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible) * Any history of ventricular fibrillation or torsade de pointes * Bradycardia defined as heart rate (HR)< 50 bpm. Patients with pacemakers are eligible if HR >/= 50 bpm. * Screening electrocardiogram (ECG) with a corrected QT interval (QTc) or QTcF > 450 msec * Right bundle branch block + left anterior hemiblock (bifascicular block) * Patients with myocardial infarction or unstable angina </= 6 months prior to starting study drug * Other clinically significant heart disease (e.g., Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study:\r\n* Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Grated acquisition (MUGA) scan or echocardiogram (ECHO)\r\n* ST depression or elevation of >= 1.5 mm in 2 or more leads\r\n* Congenital long QT syndrome\r\n* History or presence of ventricular arrhythmias or atrial fibrillation\r\n* Clinically significant resting bradycardia (< 50 beats per minutes)\r\n* Corrected QT interval (QTc) > 480 msec on screening electrocardiogram (ECG)\r\n* Complete left bundle branch block\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Unstable angina pectoris =<6 months prior to starting study drug\r\n* Acute myocardial infarction =< 6 months prior to starting study drug\r\n* Other clinically significant heart disease such as congestive heart failure requiring treatment (New York Heart Association [NYHA] class III or IV)
Other clinically significant heart disease (i.e., Grade ?3 hypertension, history of labile hypertension, or poor compliance with an anti-hypertensive regimen)
New York Heart Association (NYHA) cardiac class 3-4 heart disease as well as impaired cardiac function defined as: left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition scan (MUGA) scan or electrocardiogram; complete left bundle branch block; use of cardiac pacemaker; ST depression of > 1 mm in 2 or more leads and/or T wave inversions in 2 or more continuous leads; congenital long QT syndrome; history of, or presence of significant ventricular or atrial tachyarrhythmias; clinically significant resting bradycardia (< 50 beats per minute [bpm]); corrected QT (QTc) > 450 msec on screening electrocardiogram (ECG) (using the Fridericia QTc [QTcF] formula); right bundle branch block plus left anterior hemiblock, bifascicular block; myocardial infarction within 12 months prior to starting AMN107 (nilotinib); unstable angina diagnosed or treated within the past 12 months; other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, history of arrhythmia (including ventricular fibrillation or torsade de pointes), bradycardia < 50 beats per minute (bpm), screening electrocardiogram (ECG) with prolonged corrected QT (QTc) or uncontrolled hypertension
Impaired cardiac function including any one of the following: a. inability to monitor the QT interval on electrocardiogram (ECG), b. congenital long QT syndrome or a known family history of long QT syndrome, c. clinically significant resting brachycardia (< 45 beats per minute), d. QTc > 480 msec on baseline ECG; if QTc > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc, e. impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following: history of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) < 6 months prior to screening, symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality < 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia
Other clinically significant heart disease (e.g., CHF NY Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).
Impaired cardiac function or significant heart disease, including any one of the following:\r\n* Angina pectoris within 3 months\r\n* Acute myocardial infarction within 3 months\r\n* Corrected QT (QTc) > 450 msec on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* Other clinically significant heart disease (e.g. heart failure, uncontrolled/labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment)\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm); patients with pacemakers are eligible if resting HR >= 50 bpm\r\n* Screening electrocardiogram (ECG) with a corrected QT with Fridericia's formula (QTcF) > 480 msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina =< 6 months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following: congestive heart failure, angina pectoris within 3 months, acute myocardial infarction within 3 months, Fridericia corrected QT interval (QTcF) > 450 milliseconds (msec) for males and > 470 msec for females on the screening electrocardiogram (ECG), history of clinically significant ECG abnormalities, family history of prolonged QT-interval syndrome, or other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment)\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm); patients with pacemakers are eligible if HR >= 50 bpm\r\n* Screening electrocardiogram (ECG) with a QTc > 450 msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina =< 6 months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Any of the following concurrent severe and/or uncontrolled medical conditions that could compromise participation in the study: \r\n* ST depression or elevation of >= 1.5 mm in 2 or more leads\r\n* Congenital long QT syndrome\r\n* History or presence of sustained ventricular arrhythmias or atrial fibrillation\r\n* Clinically significant resting bradycardia (< 50 beats per minutes)\r\n* Corrected QT interval (QTc) > 480 msec on screening electrocardiogram (ECG)\r\n* Complete left bundle branch block\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Unstable angina pectoris =< 6 months prior to starting study drug\r\n* Acute myocardial infarction =< 6 months prior to starting study drug\r\n* Other clinically significant heart disease such as congestive heart failure requiring treatment (New York Heart Association [NYHA] class III or IV) or uncontrolled hypertension (please refer to World Health Organization [WHO]-International Society of Hypertension [ISH] guidelines)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: history or presence of sustained ventricular tachyarrhythmia; any history of ventricular fibrillation or torsade de pointes; bradycardia defined as heart rate (HR) < 50 beats per minute (bpm); patients with pacemakers are eligible if HR >= 50 bpm; screening electrocardiogram (ECG) with a corrected QT interval (QTc) > 450 msec; right bundle branch block + left anterior hemiblock (bifascicular block); patients with myocardial infarction or unstable angina =< 6 months prior to starting study drug; other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within 3 months\r\n* Acute myocardial infarction within 3 months\r\n* Corrected QT (QTc) > 450 msec for males and > 470 msec for females on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor adherence with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) < 45 beats per minute (bpm); patients with pacemakers are eligible if HR >= 45 bpm\r\n* Screening electrocardiogram with a QT corrected for Fridericia's formula (QTcF) >= 480 msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina =< 12 months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., Classification of Heart failure [CHF] New York Heart Association class III or IV, uncontrolled hypertension) as per discretion of principal investigator and/or treating physician\r\n* Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug with the exception of drugs that are required for hematopoietic cell transplantation (HCT) patients
Cardiac criteria such as unstable angina, myocardial infarction within 6 months of screening, NY Heart Association Class 1 or 2 heart failure, QTc greater than 470 msec, congenital long Qt syndrome, symptomatic orthostatic hypotension within 6 months of screening, uncontrolled hypertension, or clinically important abnormalities in heart rhythm, conduction, morphology of resting ECG